拜瑪林製藥 BMRN 深 滬
等待開盤 09-06 09:30:00 美东时间
57.77
+1.020
+1.80%
華盛通- 最 高58.03
- 今 開56.64
- 成交量 146.46万股
- 最 低 56.58
- 昨 收 56.75
- 總市值 110.92亿
- 52周最高 78.00
- 市盈率 靜 26.17
- 換手率 0.76%
- 52周最低 52.93
- 委 比 -98.38%
- 總股本 1.92亿
- 歷史最高 151.75
- 量 比 0.91
- 振 幅 2.56%
- 歷史最低 23.735
- 每 手 1
- 風險率 6.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Driving the Market Sentiment Around BioMarin Pharmaceutical?
BioMarin Pharmaceutical's (NYSE:BMRN) short percent of float has fallen 3.68% s...
08-30 03:00
“30年一遇”的估值洼地！Evercore ISI：美股医疗股正上演历史性熊市反弹 或是更大牛市前兆
Evercore ISI分析师表示，医疗保健板块近期显现初步复苏信号。此前，该板块相对于标普500指数的估值折价幅度创下30年来新高。
08-20 08:56
Health care stocks show signs of recovery after prolonged slump – Evercore ISI
The health care sector (NYSEARCA:XLV) is showing early signs of recovery after experiencing its largest valuation discount to the S&P 500 (SP500) in 30 years, according to Evercore ISI analysts. Since...
08-20 03:48
索罗斯投资组合新进高盛、摩根大通等
每经AI快讯，索罗斯旗下资产管理机构近日披露的13F报告显示，其投资组合价值60.2亿美元，较上一季度76.5亿美元环比减少。 该机构一季度新进CEREVEL...
08-15 06:46
BioMarin Announces Resignation of Chief Accounting Officer
The latest update is out from BioMarin Pharmaceutical ( ($BMRN) ). On August 5,...
08-12 04:44
聆听患者心声 传递生命温度
（来源：中国医药报） 转自：中国医药报 □ 本报实习记者 薛静文 7月26日上午，山东临沂费县新时代宾馆的一间小会议室内，一场特殊的宣讲会正在进行，大屏幕上...
08-07 08:17
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030
BioMarin beats Q2 expectations on strong enzyme therapy sales and raises full-year earnings and revenue guidance amid continued Voxzogo growth.
08-06 01:11
UBS Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $114
UBS analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $113 to $114.
08-05 21:06
BioMarin Pharmaceutical Raises FY2025 Adj EPS Guidance from $4.20-$4.40 to $4.40-$4.55 vs $3.45 Est; Raises FY2025 Sales Guidance from $3.100B-$3.200B to $3.125B-$3.200B vs $3.141B Est
BioMarin Pharmaceutical (NASDAQ:BMRN) raises FY2025 Adj EPS guidance from $4.20-$4.40 to $4.40-$4.55 vs $3.45 analyst estimate. Raises FY2025 sales outlook from $3.100 billion-$3.200 billion to $3.125 billion-$3.200
08-05 04:04
